With an extensive scientific background in neurodegeneration, especially in amyotrophic lateral sclerosis (ALS), Kim Staats is driven to move safe and effective therapeutic strategies to patients with ALS. She obtained her master’s degrees at the Free University of Amsterdam and her Ph.D. at the University of Leuven, Belgium, and is pursuing an M.S. in regulatory science at the University of Southern California. She consults for biotech and is driven to contribute to the speedy progression of therapeutic strategies to market.